Insiders, Pharma

Biopharma BD teams are speeding into the fast lane — cash in hand — as dealmaking continues to heat up in Q1 offensive

The charts for dealmaking in biopharma now are being redrawn as the industry heads up into record-setting territory.

Our numbers cruncher Chris Dokomajilar, who runs DealForma, assessed the figures for Q1 the other day and came up with $38 billion in total — upfront, equity and milestones — from 282 deals. That’s up from the last record, $33 billion in Q4 2018, from 324 deals.

Cash out of those deals came in at a chart-topping $3.9 billion, up a tick from $3.8 billion at the end of 2018 and a match with the previous record in 2012, which presaged a dip for the industry.

Endpoints Insider

Endpoints Enterprise

Unlock this article along with other benefits by subscribing to one of our paid plans.
Already a subscriber? Log in now
← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 51,200+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

VP Oncology Biology
Skyhawk Therapeutics Waltham, MA
Associate Director CMC
Elektroki Boston, MA
Director Process Development
Elektroki Boston, MA
Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT

Visit Endpoints Careers ->